While splice correction is a relatively novel therapeutic strategy for XLA, three recent studies by us and others have shown the feasibility of using ASOs for correcting BTK expression [80•, 81••, 82•]. This evidence concerns the gene BTK and Bruton-type agammaglobulinemia.